Search results for "second line"

showing 6 items of 26 documents

Second-Line Endocrine Treatment

1988

It was a milestone of cancer therapy in general when Huggins et al. [1] in 1941 first reported the beneficial clinical effects of bilateral orchiectomy in patients with prostate cancer, and the use of castration or estrogens as standard therapy remained the first- line treatment for many years. It was furthermore the beginning of a development which, over the following decades, led to the manipulation of testicular androgen synthesis and to attempts to eliminate other possible sources of male hormones.

Oncologymedicine.medical_specialtybusiness.industryCyproterone acetatemedicine.diseasechemistry.chemical_compoundProstate cancerAndrogen synthesisCastrationSecond linechemistryInternal medicinemedicineEndocrine systemMedroxyprogesterone acetatebusinessHormonemedicine.drug
researchProduct

Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the s…

2015

Oncologymedicine.medical_specialtybusiness.industryHistologySubgroup analysisHematologyPlaceboStage IV non-small cell lung cancerSurgeryRamucirumabDouble blindSecond lineOncologyDocetaxelInternal medicinemedicinebusinessmedicine.drug
researchProduct

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study

2021

<b><i>Introduction:</i></b> In the REFLECT trial, lenvatinib was found to be noninferior compared to sorafenib in terms of overall survival. Here, we analyze the effects of lenvatinib in the real-life experience of several centers across the world and identify clinical factors that could be significantly associated with survival outcomes. <b><i>Methods:</i></b> The study population was derived from retrospectively collected data of HCC patients treated with lenvatinib. The overall cohort included western and eastern populations from 23 center in five countries. <b><i>Results:</i></b> We included 1,325 patients with HCC …

Second lineSettore MED/12 - GastroenterologiaOncologyHepatologyHepatocellular carcinomaLenvatinibNonalcoholic fatty liver diseaseTyrosine kinase inhibitors.ALBINonalcoholic steatohepatitiNeutrophils to lymphocyte ratioOutcome
researchProduct

Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations

2021

Introduction: In patients with primary immune thrombocytopenia (ITP), a short course of steroids is routinely given as first-line therapy. However, the response is often transient and additional therapy is usually needed. Thrombopoietin receptor agonists (TPO-RAs) are frequently used as second-line therapy, although there is little clinical guidance on the timing of their administration and on tapering/discontinuation of the drug. To provide clinical recommendations, we used the Delphi technique to obtain consensus for statements regarding administration and on tapering/discontinuation of second-line TPO-RAs among a group of Italian clinicians with expertise in management of ITP. Methods: T…

Thrombopoietin Receptor Agoniststherapybusiness.industryconsensus Delphi immune thrombocytopenia management second line therapy thrombopoietin receptor agonistsfood and beveragesconsensus; Delphi; immune thrombocytopenia; management; second line; therapy; thrombopoietin receptor agonistsHematologySettore MED/15DelphiImmune thrombocytopeniaSecond lineimmune thrombocytopeniaconsensusImmunologyconsensuMedicinethrombopoietin receptor agonistsDiseases of the blood and blood-forming organsIn patientsecond lineRC633-647.5businessmanagementOriginal Research
researchProduct

A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?

2012

Abstract Background Ovarian cancer (OC) is the sixth most common cancer in women. Currently, carboplatin/paclitaxel ± bevacizumab is the cornerstone of front-line treatment. Conversely, the therapeutic options for recurrent or progressive disease are not well defined. For platinum-sensitive patients the best therapeutic approach is still a re-challenge with a platinum-based regimen. Pegylated liposomal doxorubicin (PLD), is considered one of the most active therapeutic options for recurrent or progressive OC. In this retrospective mono-institutional analysis, we evaluated the impact of PLD on the outcome of OC patients. Patients and methods We performed the retrospective study on a cohort o…

medicine.medical_specialtyBevacizumabUrologySecond line treatmentchemistry.chemical_compoundOvarian cancerPegylated liposomal doxorubicinObstetrics and GynaecologymedicineStage (cooking)Systemic chemotherapyGynecologyPlatinum refractory patientsbusiness.industryResearchObstetrics and GynecologyCancerRetrospective cohort studymedicine.diseaseCarboplatinRegimenenzymes and coenzymes (carbohydrates)OncologychemistryPlatinum refractory patientlipids (amino acids peptides and proteins)Ovarian cancerbusinessProgressive diseasemedicine.drugJournal of ovarian research
researchProduct

Dom på overføring til tvungent psykisk helsevern : en kvalitativ studie om erfaringer og utfordringer ansatte innen psykisk helse opplever i forhold …

2016

Masteroppgave psykisk helsearbeid - Universitetet i Agder 2016 Background: The subject of this study is «Sentencing to compulsory mental health care». The choice of subject is sprung from a desire to gain a better knowledge of the challenges related to providing a good service for patients sentenced to compulsory mental health care (TPH). At the same time the study is seeking a more comprehensive understanding of the already known challenges concerning the collaboration between the first and second line services providing for this group of patients. The study's findings are discussed in light of a dialogical perspective of interaction. Selection and method: Qualitative study using participa…

tvungent psykisk helseverndialogfirst line servicedialoguesecond line serviceinteractionVDP::Medical disciplines: 700::Health sciences: 800Freireforensic psychiatryførstelinjetjenestesamhandlingME504compulsory mental health caredomandrelinjetjeneste
researchProduct